-
1Academic Journal
Authors: M. I. Volkova, Al-I. S. Akel, Ya. V. Gridneva, M. Yu. Fedyanin, I. A. Pokataev, S. G. Vardanyan, R. I. Ryabinin, V. N. Galkin, М. И. Волкова, Аль-И. С. Акел, Я. В. Гриднева, М. Ю. Федянин, И. А. Покатаев, С. Г. Варданян, Р. И. Рябинин, В. Н. Галкин
Source: Malignant tumours; Том 15, № 1 (2025); 36–45 ; Злокачественные опухоли; Том 15, № 1 (2025); 36–45 ; 2587-6813 ; 2224-5057
Subject Terms: отсроченное лечение, non-metastatic prostate cancer, radical prostatectomy, radiation therapy, delayed treatment, неметастатический рак предстательной железы, радикальная простатэктомия, лучевая терапия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1447/1034; Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой 2022. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022.; Ferlay J., Colombet M., Soerjomataram I., et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144(8):1941–53. https://doi.org/10.1002/ijc.31937; Носов Д.А., Волкова М.И., Гладков О.А. и соавт. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли 2023;13(3s2):640–660. https://doi.org/10.18027/2224-5057-2023-13-3s2-1-640-660.; NCCN guideline for prostate cancer. Retrieved from https://www.nccn.org/home; Van Poppel H., Roobol M.J., Chapple C.R., et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80(6):703–711. https://doi.org/10.1016/j.eururo.2021.07.024; Hamdy F.C., Donovan J.L., Lane J.A., et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023;388(17):1547–1558. https://doi.org/10.1056/NEJMoa2214122; Bill-Axelson A., Holmberg L., Garmo H., et al. Radical prostatectomy or watchful waiting in prostate cancer — 29- year follow-up. N Engl J Med 2018;379:2319–2329. https://doi.org/10.1056/NEJMoa1807801; Wilt T.J., Brawer M.K., Jones K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367(3):203–13. https://doi.org/10.1056/NEJMoa1113162; Boyle H.J., Alibhai S., Decoster L., et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 2019;116:116–36. https://doi.org/10.1016/j.ejca.2019.04.031; Akre O., Garmo H., Adolfsson J., et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol 2011;60(3):554–563. https://doi.org/10.1016/j.eururo.2011.05.047; Albertsen P.C., Hanley J.A., Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293(17):2095–2101. https://doi.org/10.1001/jama.293.17.2095; Bylow K., Mohile S.G., Stadler W. M, Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer 2007;110(12):2604–2613. https://doi.org/10.1002/cncr.23084; Widmark A, Tomic R, Modig H, et al. Prospective randomized trial comparing external beam radiotherapy versus watchful waiting in early prostate cancer (T1b-T2, pN0, grade 1–2, M0). Presented at the 53rd Annual ASTRO Meeting, Miami Beach, FL, October 2–6, 2011; Iversen P., Madsen P.O., Corle D.K. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995;172:65–72.; Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer. N Engl J Med 2011;364(18):1708–1717. https://doi.org/10.1056/NEJMoa1011967; Van Hemelrijck M., Garmo H., Lindhagen L., et al. Quantifying the transition from active surveillance to watchful waiting among men with very low-risk prostate cancer. Eur Urol 2017;72(4):534–541. https://doi.org/10.1016/j.eururo.2016.10.031.; https://www.malignanttumors.org/jour/article/view/1447
-
2Academic Journal
Authors: M. I. Volkova, I. S. Al-Akel, Ya. V. Gridneva, R. I. Ryabinin, I. A. Pokataev, М. И. Волкова, И. С. Аль-Акел, Я. В. Гриднева, Р. И. Рябинин, И. А. Покатаев
Source: Cancer Urology; Том 20, № 3 (2024); 57-66 ; Онкоурология; Том 20, № 3 (2024); 57-66 ; 1996-1812 ; 1726-9776
Subject Terms: дистанционная лучевая терапия, non-metastatic prostate cancer, radical prostatectomy, external beam radiotherapy, неметастатический рак предстательной железы, радикальная простатэктомия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1811/1557; Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023. 239 с.; Ferlay J., Colombet M., Soerjomataram I. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144(8):1941–53. DOI:10.1002/ijc.31937; Носов Д.А., Волкова М.И., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака предстательной железы. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли 2023;13(3s2):640–60.; Houterman S., Janssen-Heijnen M.L., Verheij C.D. et al. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study. Prostate Cancer Prostatic Dis 2006;9(2):179–84. DOI:10.1038/sj.pcan.4500868; Bechis S.K., Carroll P.R., Cooperberg M.R. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011;29(2):235–41. DOI:10.1200/JCO.2010.30.2075; Preisser F., Mazzone E., Nazzani S. et al. Impact of age on perioperative outcomes at radical prostatectomy: a populationbased study. Eur Urol Focus 2020;6(6):1213–9. DOI:10.1016/j.euf.2018.12.006; Gurung P.M.S., Wang B., Hassig S. et al. Oncological and functional outcomes in patients over 70 years of age treated with robotic radical prostatectomy: a propensity-matched analysis. World J Urol 2021;39(4):1131–40. DOI:10.1007/s00345-020-03304-x; Yamada Y., Teshima T., Fujimura T. et al. Comparison of perioperative outcomes in elderly (age ≥75 years) vs. younger men undergoing robot-assisted radical prostatectomy. PLoS One 2020;15(6):e0234113. DOI:10.1371/journal.pone.0234113; Zelefsky M.J., Levin E.J., Hunt M. et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(4):1124–9. DOI:10.1016/j.ijrobp.2007.11.044; Xu N., Rossi P.J., Jani A.B. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer. Am J Clin Oncol 2011;34(1):11–5. DOI:10.1097/COC.0b013e3181cae8c6; Eade T.N., Hanlon A.L., Horwitz E.M. et al. What dose of externalbeam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007;68(3):682–9. DOI:10.1016/j.ijrobp.2007.01.008; Kumar S., Shelley M., Harrison C. et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;2006(4):CD006019. DOI:10.1002/14651858.CD006019.pub2; Spratt D.E., Malone S., Roy S. et al. Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis. J Clin Oncol 2021;39(2):136–44. DOI:10.1200/JCO.20.02438; NCCN guideline for prostate cancer. Available at: https://www.nccn.org/home; Shipley W.U., Seiferheld W., Lukka H.R. et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 2017;376(5):417–28. DOI:10.1056/NEJMoa1607529; D’Amico A.V., Chen M.H., Renshaw A.A. et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299(3):289–95. DOI:10.1001/jama.299.3.289; Denham J.W., Steigler A., Lamb D.S. et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12(5):451–9. DOI:10.1016/S1470-2045(11)70063-8; Jones C.U., Hunt D., McGowan D.G. et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365(2):107–18. DOI:10.1056/NEJMoa1012348; Horwitz E.M., Bae K., Hanks G.E. et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26(15):2497–504. DOI:10.1200/JCO.2007.14.9021; Bolla M., de Reijke T.M., Van Tienhoven G. et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360(24):2516–27. DOI:10.1056/NEJMoa0810095; Zapatero A., Guerrero A., Maldonado X. et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015;16(6):320–7. DOI:10.1016/S1470-2045(15)70272-X; Kishan A.U., Wang X., Seiferheld W. et al. Association of Gleason grade with androgen deprivation therapy duration and survival outcomes: a systematic review and patient-level meta-analysis. JAMA Oncol 2018;5(1):91–6. DOI:10.1001/jamaoncol.2018.3732; Nabid A., Carrier N., Martin A.G. et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol 2018;74(4):432–41. DOI:10.1016/j.eururo.2018.06.018; Denham J.W., Joseph D., Lamb D.S. et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol 2019;20(2):267–81. DOI:10.1016/S1470-2045(18)30757-5; Hamdy F.C., Donovan J.L., Lane J.A. et al.; ProtecT Study Group. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023;388(17):1547–58. DOI:10.1056/NEJMoa2214122; Duchesne G.M., Woo H.H., Bassett J.K. et al. Timing of androgendeprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016;17(6):727–37.; Boorjian S.A., Thompson R.H., Tollefson M.K. et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59(6):893–9. DOI:10.1016/j.eururo.2011.02.026; https://oncourology.abvpress.ru/oncur/article/view/1811